# Mechanisms and therapeutic potential of mitochondrial-targeted therapies in bone repair

**Authors:** Nanjian Xu, Weihu Ma, Guanyi Liu, Fang Yang

PMC · DOI: 10.1080/07853890.2026.2641277 · Annals of Medicine · 2026-03-13

## TL;DR

This review explores how targeting mitochondria can improve bone repair, offering a promising new strategy for treating difficult-to-heal bone defects.

## Contribution

The paper systematically reviews mitochondrial roles in bone repair and evaluates current mitochondrial-targeted therapeutic strategies.

## Key findings

- Mitochondrial dysfunction is a key factor in failed bone repair.
- Targeting mitochondria can enhance cellular energy metabolism and promote cell survival.
- Challenges include improving delivery efficiency and ensuring long-term safety.

## Abstract

Bone defect repair remains a significant challenge in orthopedics, particularly for critical-sized bone defects, which often result in nonunion. Traditional treatments have numerous limitations. Recent studies have highlighted the pivotal role of mitochondria as cellular energy and metabolic hubs influencing the function of osteoblasts, osteoclasts, and chondrocytes. Mitochondria regulate energy metabolism, ROS signaling, mitochondrial dynamics, and apoptosis, all of which are essential for maintaining proper bone function. Mitochondrial dysfunction has been identified as a key intrinsic factor contributing to the failure of bone repair. Thus, targeting mitochondria has emerged as a promising therapeutic strategy. This article systematically reviewed the various functional roles of mitochondria in bone repair and evaluated the current progress of mitochondrial-targeted therapeutic strategies. We focused on the mechanisms of action and preclinical advancements related to small molecule compounds, functionalized biomaterials, and advanced cell therapies, offering a theoretical foundation for their potential clinical application. Mitochondrial-targeted therapies show significant promise for enhancing bone repair by improving cellular energy metabolism, restoring redox homeostasis, optimizing mitochondrial quality control, and promoting cell survival. However, this field faces several challenges, including improving targeted delivery efficiency, ensuring long-term safety, and translating these strategies into clinical practice. Future research should prioritize the development of more precise delivery technologies, exploration of multi-target synergistic approaches, and rigorous clinical trials to support the practical application of mitochondrial-targeted therapies for clinical bone regeneration.

This review highlights the strong translational potential of mitochondrial-targeted therapies as a next-generation strategy for bone repair. By systematically linking specific mitochondrial dysfunctions to mechanism-based interventions. It provides a rational framework for developing treatments that enhance cellular fitness. Overcoming delivery and safety challenges through interdisciplinary efforts could revolutionize the management of critical-sized defects, particularly in compromised healing environments like aging or diabetes.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** MFN2 (mitofusin 2) [NCBI Gene 9927] {aka CMT2A, CMT2A2, CMT2A2A, CMT2A2B, CPRP1, HMSN6A}, MFN1 (mitofusin 1) [NCBI Gene 55669] {aka hfzo1, hfzo2}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}, LCN2 (lipocalin 2) [NCBI Gene 3934] {aka 24p3, MSFI, NGAL, p25}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, DLL4 (delta like canonical Notch ligand 4) [NCBI Gene 54567] {aka AOS6, delta4, hdelta2}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, MFF (mitochondrial fission factor) [NCBI Gene 56947] {aka C2orf33, EMPF2, GL004}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, OPA1 (OPA1 mitochondrial dynamin like GTPase) [NCBI Gene 4976] {aka BERHS, MGM1, MTDPS14, MTDPS14A, MTDPS14B, NPG}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, DIABLO (diablo IAP-binding mitochondrial protein) [NCBI Gene 56616] {aka DFNA64, SMAC}, DNM1L (dynamin 1 like) [NCBI Gene 10059] {aka DLP1, DRP1, DVLP, DYMPLE, EMPF, EMPF1}, OMA1 (OMA1 zinc metallopeptidase) [NCBI Gene 115209] {aka 2010001O09Rik, MPRP-1, MPRP1, YKR087C, ZMPOMA1, peptidase}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, SIRT3 (sirtuin 3) [NCBI Gene 23410] {aka SIR2L3}, Ppargc1a (PPARG coactivator 1 alpha) [NCBI Gene 83516] {aka LRPGC1, PGC-1v, PGCvf, PGCvf-1, PGCvf1, Ppargc1}, Sirt1 (sirtuin 1) [NCBI Gene 309757] {aka Sir2}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, RIPK4 (receptor interacting serine/threonine kinase 4) [NCBI Gene 54101] {aka ANKK2, ANKRD3, CHANDS, DIK, NKRD3, PKK}, FIS1 (fission, mitochondrial 1) [NCBI Gene 51024] {aka CGI-135, TTC11}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, Bnip3 (BCL2 interacting protein 3) [NCBI Gene 84480], NFATC1 (nuclear factor of activated T cells 1) [NCBI Gene 4772] {aka NF-ATC, NF-ATc1.2, NFAT2, NFATc}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, HDAC2 (histone deacetylase 2) [NCBI Gene 3066] {aka HD2, KDAC2, RPD3, YAF1}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, TFAM (transcription factor A, mitochondrial) [NCBI Gene 7019] {aka MTDPS15, MTTF1, MTTFA, TCF6, TCF6L1, TCF6L2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}
- **Diseases:** osteoporotic (MESH:D058866), Bone defect (MESH:D001847), metabolic paralysis (MESH:D010243), tumor (MESH:D009369), skeletal diseases (MESH:D004194), hypoxia (MESH:D000860), trauma (MESH:D014947), congenital deformities (MESH:D006228), infection (MESH:D007239), inflammation (MESH:D007249), osteoarthritis (MESH:D010003), mitochondrial defect (MESH:C565376), fractures (MESH:D050723), Nonunion (MESH:C538144), ischemia-reperfusion injury (MESH:D015427), diabetes (MESH:D003920), Mitochondrial dysfunction (MESH:D028361), ischemia (MESH:D007511), hyperglycemic (MESH:D006944), osteogenic dysfunction (MESH:D012516), functional impairment (MESH:D003072), Alzheimer's and Parkinson's diseases (MESH:D010300), AD (MESH:D000544), skeletal disorders (MESH:C564967), osteoporosis (MESH:D010024), cytotoxic (MESH:D064420), pain (MESH:D010146), periodontitis (MESH:D010518)
- **Chemicals:** Mdivi-1 (MESH:C000723896), silicon (MESH:D012825), superoxide anions (MESH:D013481), cysteine (MESH:D003545), MT (MESH:C555916), fatty acid (MESH:D005227), ubiquinone (MESH:D014451), TCA (MESH:D014233), T (MESH:D014316), oxygen (MESH:D010100), H2O2 (MESH:D006861), glutamate (MESH:D018698), malondialdehyde (MESH:D008315), AOC (-), hydroxyl radicals (MESH:D017665), NAD+ (MESH:D009243), MnO2 (MESH:C016552), TPP+ (MESH:C016136), phosphate (MESH:D010710), alpha-ketoglutarate (MESH:D007656), tocopherol (MESH:D024505), calcium (MESH:D002118), calcium phosphate (MESH:C020243), magnesium (MESH:D008274), NMN (MESH:D009537), glucose (MESH:D005947), lipids (MESH:D008055), oligomycin (MESH:D009840), Melatonin (MESH:D008550), cerium (MESH:D002563), copper (MESH:D003300), SRT1720 (MESH:C525422), CoQ10 (MESH:C024989), MitoQ (MESH:C429014), NR (MESH:C018613), ATP (MESH:D000255), Metformin (MESH:D008687), hydroxyapatite (MESH:D017886), acetyl-CoA (MESH:D000105), fisetin (MESH:C017875), MDA (MESH:D015104)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12990278/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12990278/full.md

## References

105 references — full list in the complete paper: https://tomesphere.com/paper/PMC12990278/full.md

---
Source: https://tomesphere.com/paper/PMC12990278